Evidence map›Paper›PMID 42581261›Full record

ReviewPharmaceutical research2026

Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches.

Petra Booij, Tarja Nurmi, Georg Pour, Jason Creasey, Ting Zhang, Julie Hash, Aeshna Amin, Cindy Duong, JoAnn Chen, Steven A Zdravkovic and 6 more

Abstract readReview
In one paragraph

Review in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Petra BooijGSK, Stevenage, UK.
Tarja NurmiBayer, Turku, Finland.
Georg PourEVER Valinject GmbH, Unterach, Austria.
Jason CreaseyMaven E&L Ltd Consulting, Stevenage, UK.
Ting ZhangAmerican Regent, New Albany, OH, USA.
Julie HashPfizer Inc., Chesterfield, MO, USA.
Aeshna AminBaxter Pharmaceuticals India Private Limited, Gujarat, India.
Cindy DuongVantive, Deerfield, IL, USA.
JoAnn ChenBaxter International Inc., Deerfield, IL, USA.
Steven A ZdravkovicVantive, Deerfield, IL, USA.
Michael HelfrichEVER Valinject GmbH, Unterach, Austria.
Tim VerdonckBaxter International Inc., Deerfield, IL, USA.
Janine MüllerOctapharma Pharmazeutika Produktionsges.m.b.H., Wien, Austria.
Alicja SobańtkaOctapharma Pharmazeutika Produktionsges.m.b.H., Wien, Austria.
Craig McKenzieGE HealthCare, Oslo, Norway.
Mary Kate BielinskiFaegre Drinker Biddle & Reath LLP, 1500 K Street NW, Suite 1100, Washington, DC, 20005, USA. Marykate.bielinski@faegredrinker.com.ORCID http://orcid.org/0009-0007-6124-2432

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving the Analytical Evaluation Threshold (AET) for leachables is critical in quantification for patient safety evaluation but presents challenges for drug products with large dosing volumes or complex matrices. This paper reviews these challenges, presents industry perspectives, and proposes scientifically justified approaches to ensure patient safety where the AET is not analytically achievable. An industry-wide survey conducted by the Extractables and Leachables Safety Information Exchange (ELSIE) Consortium among 23 member companies identified common hurdles and alternative approaches used in leachables risk assessments. Findings were supplemented with case studies and a review of current analytical and regulatory strategies. The survey identified large dosing volumes (74% respondents) and matrix complexity (68% respondents) as the primary drivers for unachievable AETs. Matrix complexity was shown to significantly impact achievable limits of quantification (LOQs), with reported LOQs ranging from < 10 parts per billion (ppb) in simple aqueous solutions to > 100 ppb in complex matrices like protein-based or lipid-based formulations. Key analytical difficulties included identifying unknown leachables, background interference, and differentiating true leachables from analytical artifacts. When conventional screening methods cannot meet the AET, a robust, scientifically rationalized alternative approach is essential. Recommendations include implementing targeted leachable studies for enhanced sensitivity, using simulation studies to predict leachable profiles without matrix interference, and applying predictive modelling. For therapies addressing life-threatening conditions, a risk-benefit analysis leveraging the "less than lifetime" (LTL) concept may justify higher thresholds. Demonstrating rigorous method development efforts and providing scientific justification for the chosen strategy is crucial for regulatory alignment and ensuring patient safety.

Indexed as

Drug ContaminationDrug IndustryHumansPatient SafetyPharmaceutical PreparationsRisk AssessmentPharmaceutical PreparationsAnalytical Evaluation Threshold (AET)leachablesmatrix complexityregulatory strategiesrisk assessment

Identifiers

PMID42581261
PMCPMC13593624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.